Jazz Pharmaceuticals Cash Flow Statement
NASDAQ: JAZZHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Jazz Pharmaceuticals free cash flow
In fiscal 2025, Jazz Pharmaceuticals generated $1.36 billion of operating cash flow and spent $58.8 million on capital expenditures. That left free cash flow of $1.30 billion, a free-cash-flow margin of 30.4% of revenue. Free cash flow was down 4.5% from the prior year's $1.36 billion.
Jazz Pharmaceuticals returned $125.0 million to shareholders through share repurchases, equal to 10% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Jazz Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -356.15M | 560.12M | 414.83M | -224.06M | -329.67M | 238.62M | 523.37M | 447.10M | 487.85M | 396.83M |
| Net Income growth (YoY) | -163.58% | +35.02% | — | — | -238.16% | -54.41% | +17.06% | -8.35% | +22.94% | +20.42% |
| Depreciation & Amortization | 41.60M | 32.80M | 30.40M | 30.30M | 26.70M | 18.70M | 15.30M | 15.20M | 13.10M | 11.80M |
| Stock-Based Compensation | 291.13M | 248.04M | 226.84M | 222.00M | 189.01M | 121.00M | 110.56M | 102.44M | 106.90M | 98.77M |
| Change in Working Capital | -95.42M | -148.14M | -206.88M | 48.68M | -27.84M | -111.40M | -156.97M | 28.80M | -8.62M | -47.29M |
| Operating Cash Flow | 1.36B | 1.40B | 1.09B | 1.27B | 778.51M | 899.65M | 776.40M | 798.90M | 693.09M | 592.39M |
| Capital Expenditures | -58.75M | -38.07M | -23.96M | -29.05M | -27.64M | -15.00M | -40.13M | -20.37M | -28.95M | -9.69M |
| Investing Cash Flow | -1.51B | -508.19M | -163.06M | -446.23M | -5.21B | -1.01B | -155.30M | -394.49M | -268.95M | -1.75B |
| Share Repurchases | -125.02M | -311.43M | -269.76M | -54.00K | 0 | -146.54M | -301.45M | -523.67M | -98.80M | -278.30M |
| Debt Issued | — | — | 0 | 0 | 1.47B | 0 | 0 | 0 | 559.39M | 994.65M |
| Financing Cash Flow | -873.38M | 20.52M | -305.25M | -529.49M | 3.97B | 528.07M | -293.75M | -479.13M | -409.11M | 540.99M |
| Net Change in Cash | -1.02B | 906.55M | 624.83M | 290.03M | -466.32M | 420.43M | 327.72M | -76.41M | 20.07M | -622.82M |
| Free Cash Flow | 1.30B | 1.36B | 1.07B | 1.24B | 750.87M | 884.64M | 736.27M | 778.53M | 664.14M | 582.70M |
This table shows 10 annual periods of Jazz Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow JAZZ's reporting calendar. What is a cash flow statement?